Imvax, Inc.

Imvax, Inc. | 1,237 followers on LinkedIn. Imvax is a clinical-stage biotechnology company with a unique immunotherapy approach to solid tumors. | The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company’s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.